Get email alerts on the Pharmaceuticals Alzheimers topic
No spam. Unsubscribe anytime.
Researcher outlines how new Alzheimer’s drugs work, flags affordability and access concerns
Summary
Dr. Gohar Azhar presented new Alzheimer’s medications to the advisory council, explaining mechanisms, treatment duration, and criteria for who receives therapy while highlighting concerns about affordability and patient selection.
Dr. Gohar Azhar, Co‑Director of Cardiovascular Aging Research in the Reynolds Department of Geriatrics and Institute on Aging, briefed the Alzheimer's Disease and Dementia Advisory Council on recently developed pharmaceutical treatments for Alzheimer’s disease. Azhar described how the medications work, typical treatment duration, and the clinical criteria used to determine which patients are eligible for therapy. Azhar also raised concerns about affordability and the mechanisms by which scarce supplies might be allocated.
The presentation prompted questions about access and cost. Council members discussed the need for clear guidance on patient selection and for assessing how state programs might help cover treatment for eligible Arkansans. The council did not take formal action on funding or access at this meeting; members asked staff and stakeholders to provide additional information at a future session.
AI generated
The text on this page is AI generated. Summaries, highlights, analysis, and video transcripts are all produced from the original source material.
AI can make mistakes, so if you spot one, and we will fix it for everyone.
Note: the source content is unaltered by us. Any content source we link to, be it a video, an audio recording, or a document, is presented exactly as its publisher released it. That publisher is usually a government body, sometimes an individual official or another organisation.
